Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYMPAZAN vs SEIZALAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYMPAZAN (clobazam) is a benzodiazepine that potentiates GABAergic inhibition via binding to the GABA-A receptor at the benzodiazepine site, enhancing chloride ion influx and neuronal hyperpolarization.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older,Off-label: adjunctive therapy for other epileptic syndromes, anxiety disorders, and acute repetitive seizures
Status epilepticus,Acute repetitive seizures,Seizure clusters
10-20 mg orally three times daily (maximum 60 mg/day). If switching from another benzodiazepine, use equivalent dose.
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
Terminal elimination half-life is approximately 20-30 minutes sublingually, prolonged to 2-3 hours in hepatic impairment. Clinical context: Short t½ necessitates repeated dosing for seizure clusters.
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
Primarily metabolized by CYP3A4 and CYP2C19 to N-desmethylclobazam, an active metabolite. N-desmethylclobazam is further metabolized by CYP2C19.
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Primarily renal excretion of unchanged drug (approximately 60-70%), with minor fecal elimination (10-15%) and metabolism.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
Approximately 90-95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 98% bound to albumin.
Vd is 1-2 L/kg, indicating extensive tissue distribution beyond plasma volume.
1.0–1.5 L/kg; reflects extensive tissue distribution.
Sublingual and buccal: 100% bioequivalent to intravenous; intranasal: approximately 80%.
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution and consider dose reduction; specific guidelines not established.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), reduce dose by 50% or administer with caution, as clobazam is extensively metabolized in the liver.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Based on body weight: 5 mg orally once daily for <30 kg, increase to 10 mg daily after 2 weeks if needed (max 20 mg/day). For ≥30 kg, 5-10 mg once daily initially, titrate to 20 mg/day (max 40 mg/day).
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
Initiate at 5 mg once daily, titrate slowly due to increased sensitivity to benzodiazepines and risk of falls. Maximum dose generally not to exceed 20 mg/day.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
Concomitant use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
Respiratory depression,Sedation and somnolence,Risk of abuse, misuse, and addiction,Dependence and withdrawal reactions,Suicidal thoughts or behavior
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Hypersensitivity to clobazam or any component of the formulation,Severe hepatic impairment (Child-Pugh Class C)
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
Avoid grapefruit and grapefruit juice as they may increase levels of clobazam and its active metabolite. No other significant food interactions known.
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
Benzodiazepines are generally associated with increased risk of oral clefts when used in the first trimester. Use in the third trimester may cause neonatal sedation, withdrawal, or floppy infant syndrome. Specific fetal risk data for clobazam (Sympazan) are limited.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
Clobazam is excreted in breast milk. The milk-to-plasma ratio is approximately 0.3 to 0.5. Monitor infant for sedation, poor feeding, and weight gain. Avoid breastfeeding if possible.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
Increased clearance of clobazam in pregnancy may require dose adjustments; monitor therapeutic response and adjust accordingly.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
Clobazam oral film (SYMPAZAN) is a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older. It is available as a rapidly dissolving film that can be placed on the tongue. The active metabolite N-desmethylclobazam is primarily renally excreted; adjust dose in renal impairment. Avoid abrupt discontinuation due to risk of withdrawal seizures. CYP2C19 poor metabolizers have significantly higher exposure to the active metabolite; consider dose reduction. Can cause sedation, dizziness, and somnolence; monitor for respiratory depression especially with other CNS depressants. Abuse potential exists; use with caution in patients with history of substance abuse.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
Place the film on your tongue where it will dissolve quickly; do not chew or swallow it whole.,Take this medication exactly as prescribed; do not increase the dose or stop suddenly without talking to your doctor to avoid withdrawal seizures.,Avoid driving or operating heavy machinery until you know how this drug affects you, as it may cause drowsiness, dizziness, or blurred vision.,Avoid alcohol and other sedating medications while taking SYMPAZAN, as they can increase the risk of severe drowsiness and breathing problems.,Tell your doctor if you have kidney or liver disease, or if you have a history of substance abuse or depression.,If you miss a dose, take it as soon as you remember; if it is close to the next dose, skip the missed dose and continue your regular schedule. Do not double the dose.,Store the film at room temperature away from moisture and heat; keep each film in its sealed pouch until ready to use.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYMPAZAN vs SEIZALAM, answered by our medical review team.
SYMPAZAN is a Benzodiazepine Anticonvulsant that works by SYMPAZAN (clobazam) is a benzodiazepine that potentiates GABAergic inhibition via binding to the GABA-A receptor at the benzodiazepine site, enhancing chloride ion influx and neuronal hyperpolarization.. SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYMPAZAN and SEIZALAM depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYMPAZAN is: 10-20 mg orally three times daily (maximum 60 mg/day). If switching from another benzodiazepine, use equivalent dose.. The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYMPAZAN and SEIZALAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYMPAZAN is classified as Category C. Benzodiazepines are generally associated with increased risk of oral clefts when used in the first trimester. Use in the third trimester may cause neonatal sedation, withdrawal, or. SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.